Drug Trial Radar · NCT06908954
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose
Last checked: Nov 20, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Mar 14, 2025
Primary completion
Feb 6, 2026
Study completion Feb 6, 2026
Sponsor
- Lead sponsor
- IpsenIndustry
- Sponsor type
- Industry
- First posted
- Apr 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main aim of this study is to understand how moderate and severe liver impairment (based on the Child-Pugh classification) affects the body's processing of a single dose of 10 mg maximum of palovarotene, compared to healthy participants with normal liver function. The study will also assess the safety and tolerability of the single dose of palovarotene. Participants will be enrolled in stages and divided into three groups based on their liver function: * Group 1: Healthy participants with normal liver function * Group 2: Participants with moderate liver impairment * Group 3: Participants with severe liver impairment (only enrolled if Group 2 results are safe and acceptable) Blood samples will be taken to assess how the drug binds to proteins in the blood. Participants will undergo various safety checks and procedures. Participants will stay in the clinical unit until Day 5 for these assessments and will return on Day 10 for a final visit.
Conditions
- Hepatic Impairment
- Healthy
Interventions
PalovaroteneDrug
A single dose of maximum 10 mg of palovarotene will be administered orally on Day 1 to healthy control participants with normal hepatic function
PalovaroteneDrug
A single 10 mg dose of palovarotene will be administered orally on Day 1 to Moderate hepatic impaired participants (Child-Pugh class B)
PalovaroteneDrug
A single 10 mg dose of either 5 mg or 10 mg of palovarotene will be administered orally on Day 1 to Severe hepatic impaired participants (Child-Pugh class C).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma drug concentration (Cmax)Time frame: Over 96 hours postdose
- Unbound fraction of drug in plasma (fu)Time frame: Over 96 hours postdose
- Time to maximum observed plasma concentration (Tmax)Time frame: Over 96 hours postdose
- Area under the plasma concentration-time curve (AUC) from time 0 to infinity (AUC0-∞)Time frame: Over 96 hours postdose
- AUC from 0 to time t corresponding to the last quantifiable concentration (AUC0-tlast)Time frame: Over 96 hours postdose
- Apparent terminal elimination half life (T1/2)Time frame: Over 96 hours postdose
- Apparent terminal elimination rate constant (λz).Time frame: Over 96 hours postdose
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
ERG - Clinical Pharmacology of Miami
Miami, Florida
Orlando Clinical Research Center
Orlando, Florida
American Research Corporation/Texas Liver Institute
San Antonio, Texas
Pinnacle Clinical Research
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.